Boston Scientific Launches Emerge PTCA Balloon Dilatation Catheter in the U.S.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions


September 28, 2012

Boston Scientific Corp. received U.S. Food and Drug Administration (FDA) clearance for the Emerge percutaneous transluminal coronary angioplasty (PTCA) balloon dilatation catheter in September 2012. The Emerge catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries. Both monorail and over-the-wire (OTW) options are available. The Emerge catheter has been commercially available in CE mark countries since early 2012.

The Emerge balloon catheter is available in a wide array of balloon diameters from 1.5 mm up to 4.0 mm, with balloon lengths ranging from 8 mm up to 30 mm. Both the monorail and OTW catheters are available with two distinct shaft technologies designed to provide versatility in addressing different clinical situations. The "Push Technology" (1.5 mm) offers a single-segment inner shaft for enhanced pushability. The "Workhorse Technology" (1.5 mm to 4.0 mm) features a bi-segment inner shaft designed for excellent deliverability without sacrificing push.

Coronary artery disease represents the leading cause of death in the United States, accounting for more than 870,000 deaths each year. PTCA balloon dilatation catheters are used in coronary angioplasty and stenting procedures to open arteries blocked by atherosclerosis, which if left untreated can cause angina and heart attack.

For more information: